Acute ischemic stroke happens when a blood clot blocks an artery supplying part of the brain, cutting off oxygen and killing neurons within minutes. It accounts for roughly 85 percent of all strokes, and the treatments available today can dramatically reduce disability, but only if they reach the patient fast enough. The science behind recognizing, treating, and recovering from an ischemic stroke has changed substantially in the past decade, and much of what determines a person’s outcome comes down to decisions made in the first few hours.
What Happens Inside the Brain During a Stroke
When a clot lodges in a brain artery, the tissue directly downstream loses its blood supply almost immediately. That core zone of the brain begins dying within minutes. Surrounding it, though, is a larger region called the penumbra, where blood flow is reduced but not completely gone. Neurons in the penumbra are stressed and electrically silent, but they are not dead yet. They can survive for hours if some trickle of blood continues to reach them. The entire goal of acute stroke treatment is to restore blood flow before the penumbra collapses into irreversible damage.
The damage is not just about oxygen starvation. A cascade of harmful processes kicks in almost immediately, including runaway inflammation, the release of toxic molecules, and swelling. Paradoxically, when blood flow is eventually restored, the sudden return of oxygen can trigger a second wave of injury through oxidative stress, immune cell infiltration, and disruption of the blood-brain barrier, which can lead to brain swelling or bleeding into the damaged tissue.1PubMed Central. Ischemia-reperfusion Injury in the Brain: Mechanisms and Potential Therapeutic Strategies This reperfusion injury is one reason why stroke treatment requires careful monitoring even after the clot is cleared.
Why Strokes Happen and the Main Subtypes
Not all ischemic strokes are the same. The most widely used classification system identifies five subtypes based on the underlying cause.2PubMed. Classification of subtype of acute ischemic stroke. Definitions for use in a multicenter clinical trial. TOAST. Trial of Org 10172 in Acute Stroke Treatment Knowing the cause matters because it determines what kind of prevention a patient needs afterward.
- Large-artery atherosclerosis: Fatty plaque builds up in a major artery to the brain, eventually narrowing it enough for a clot to form or a chunk of plaque to break off and travel upstream.
- Cardioembolism: A clot forms in the heart, often because of an irregular heartbeat like atrial fibrillation, and travels to the brain.
- Small-vessel occlusion: Tiny arteries deep inside the brain become blocked, usually from long-standing high blood pressure or diabetes. These tend to cause smaller strokes but can still be disabling.
- Other determined cause: Less common conditions such as blood-clotting disorders, artery dissections, or infections.
- Undetermined cause: Sometimes called cryptogenic stroke, this category applies when no clear cause is found despite a thorough workup, or when more than one plausible cause exists.
The cryptogenic category is more significant than it sounds. In younger adults especially, a patent foramen ovale, a small hole between the upper chambers of the heart that normally closes after birth, can allow clots from the veins to cross into the arterial circulation and reach the brain. A meta-analysis of high-quality trials found that closing this hole with a catheter-delivered device reduced the absolute risk of another stroke by about three percent compared with medication alone.3PubMed. Device Closure Versus Medical Therapy Alone for Patent Foramen Ovale in Patients With Cryptogenic Stroke: A Systematic Review and Meta-analysis That may sound modest, but for a young person facing decades of recurrence risk, it is a meaningful reduction.
Recognizing a Stroke and Getting Help
Speed is everything. The phrase “time is brain” is not an exaggeration: roughly two million neurons die every minute during an untreated large-vessel stroke. Public awareness campaigns have popularized the FAST acronym (Face drooping, Arm weakness, Speech difficulty, Time to call emergency services), and it remains a useful tool for bystanders. But paramedics need more precise instruments. A head-to-head comparison of seven prehospital screening scales found that the best-performing tools caught around 84 percent of stroke cases, though their ability to rule out non-stroke mimics was more limited, with specificities in the range of 28 to 49 percent.4PubMed Central. Prehospital stroke detection scales: A head-to-head comparison of 7 scales in patients with suspected stroke In practice, this means paramedics cast a wide net: it is better to rush someone to the hospital who turns out not to be having a stroke than to miss a real one.
A separate challenge is identifying which strokes involve a large-vessel blockage, because those patients benefit from a specialized procedure (thrombectomy) available only at certain hospitals. Scales designed for this purpose, such as FAST-ED, show a tradeoff: they are more specific, correctly ruling out large-vessel strokes about 89 percent of the time, but they miss a fair number of true cases, catching roughly 60 percent.5PubMed Central. Field Assessment Stroke Triage for Emergency Destination: A Simple and Accurate Prehospital Scale to Detect Large Vessel Occlusion Strokes Getting this triage decision right in the field can mean the difference between a patient arriving at a hospital that can treat them and one that cannot.
How Imaging Guides Treatment Decisions
Once a patient reaches the emergency department, a CT scan of the head is performed within minutes. The first priority is ruling out a hemorrhagic stroke (bleeding in the brain), which looks completely different on imaging and requires the opposite treatment approach. A plain CT scan can identify bleeding almost immediately, but early ischemic strokes are often invisible on a standard scan for the first several hours.
This is where CT perfusion imaging becomes critical. By injecting contrast dye and watching how it flows through the brain, radiologists can map both the dead core and the salvageable penumbra. Research has converged on specific thresholds that best distinguish these zones: a delay in blood arrival of more than three seconds identifies the penumbra, while a severely reduced blood flow (less than 30 percent of normal) within that delayed area marks the irreversible core.6PubMed. Whole-Brain CT Perfusion to Quantify Acute Ischemic Penumbra and Core7Scientific Reports. Defining Core and Penumbra in Ischemic Stroke: A Voxel- and Volume-Based Analysis of Whole Brain CT Perfusion When perfusion imaging shows a large penumbra relative to the core, there is brain worth saving, and aggressive treatment is justified even many hours after symptom onset.
Artificial intelligence is increasingly integrated into this process. A multicenter study of an AI-based stroke imaging tool found it achieved about 95 percent accuracy for detecting bleeding on plain CT and 86 percent accuracy for identifying large-vessel blockages on CT angiography.8European Journal of Radiology Open. Performance of an artificial intelligence tool for multi-step acute stroke imaging: A multicenter diagnostic study These tools do not replace radiologists, but they can flag critical findings within seconds and alert the stroke team before a human has even opened the images, shaving minutes off the clock when every minute counts.9Journal of NeuroInterventional Surgery. Artificial intelligence to diagnose ischemic stroke and identify large vessel occlusions: a systematic review
Clot-Busting Drugs
Intravenous thrombolysis, the injection of a drug that dissolves blood clots, has been the backbone of acute stroke treatment since alteplase was approved in the 1990s. For decades, alteplase was the only option and had to be given within three hours of symptom onset. That window eventually expanded to four-and-a-half hours for eligible patients, and the landscape is now shifting further. Tenecteplase, a newer clot-busting drug, can be given as a single quick injection rather than a one-hour infusion. A systematic review found tenecteplase performed as well as alteplase, and in some respects better, with comparable or lower rates of post-treatment bleeding, similar functional outcomes at 90 days, and better rates of reopening the blocked vessel when followed by thrombectomy.10PubMed Central. Tenecteplase vs. alteplase for acute ischemic stroke: a systematic review The practical advantages are significant: a single injection is faster to administer, easier to prepare, and better suited for prehospital use.
The therapeutic window has also expanded beyond the original time limits, driven by imaging rather than the clock alone. When perfusion imaging shows salvageable brain tissue, treatment can be considered well beyond traditional cutoffs. The era of a rigid time window for thrombolysis is giving way to a more individualized approach based on what the brain scans actually show.11BMJ. 30 years of thrombolysis for ischaemic stroke: expanded agents, widened windows and accelerated delivery
Mechanical Thrombectomy
For strokes caused by a large clot in a major brain artery, clot-busting drugs alone often are not enough. Mechanical thrombectomy involves threading a catheter from the groin up into the brain’s arteries and physically pulling the clot out. This procedure transformed stroke care when landmark trials published around 2015 showed dramatic improvements in outcomes. It was initially restricted to patients treated within six hours, but newer evidence pushed the window out to 24 hours for patients selected by perfusion imaging showing salvageable brain tissue.
Outcomes for patients treated within six hours and those treated in the extended window (up to 24 hours) appear broadly similar when imaging-based selection is used. One study found no significant differences in good outcomes (about 42 versus 53 percent), severe bleeding complications (about 6.5 versus 4.6 percent), or death (about 3 versus 6 percent) between early and late treatment groups.12PubMed Central. Mechanical Thrombectomy Up to 24 Hours in Large Vessel Occlusions and Infarct Velocity Assessment Even patients who do not neatly fit the profiles used in the most rigorous trials may benefit: a multicenter cohort study found that thrombectomy in the late window improved functional outcomes and reduced 90-day mortality compared with medical treatment alone.13PubMed Central. Mechanical Thrombectomy Versus Best Medical Treatment in the Late Time Window in Non-DEFUSE-Non-DAWN Patients: A Multicenter Cohort Study
Age is one factor that influences how well people do after thrombectomy. In a study of patients treated beyond six hours, about 73 percent of younger patients achieved functional independence at three months, compared with about 31 percent of older patients.14PubMed Central. Extended Time Window (>6 Hour) Mechanical Thrombectomy; Good Clinical Outcome in the Younger Age Population in Thrombectomy Cases: Relationship between Age and Prognosis This does not mean older patients should not be treated, as thrombectomy can still be life-saving, but expectations about recovery differ.
Blood Pressure Management in the First Hours
Blood pressure almost always spikes during an acute stroke, and managing it is trickier than you might expect. The instinct to lower dangerously high blood pressure has to be balanced against the brain’s need for as much blood flow as possible through narrowed or blocked arteries. Too aggressive a drop can worsen the damage.
For patients receiving clot-busting drugs, guidelines from multiple international bodies converge on a consistent target: blood pressure should be brought below 185/110 before treatment begins and maintained below 180/105 for the first 24 hours.15Hypertension Research. Blood pressure management in stroke: comparative review of the 2025 AHA/ACC/AANP/ACPM/AGS/AMA/ASPC/NMA/PCNA/SGIM, 2024 ESC, 2023 ESH, and 2025 JSH guidelines For patients who are not receiving thrombolysis or thrombectomy, the threshold for intervention is much higher: treatment is generally withheld unless systolic pressure exceeds 220 or diastolic exceeds 120, and even then, the reduction is modest, typically around 15 percent in the first day. The optimal long-term blood pressure target after the acute phase remains an open question, likely depending on what type of treatment was given and the individual patient’s situation.16PubMed Central. Blood Pressure Goals in Acute Stroke
When Swelling Becomes Life-Threatening
In large strokes, brain swelling can become the most dangerous complication. The brain is encased in a rigid skull, so significant swelling compresses healthy tissue and can push brain structures downward in a process called herniation, which is often fatal. When medical measures fail to control swelling, a surgical procedure called decompressive craniectomy, temporarily removing a section of skull to give the swollen brain room to expand, can be life-saving. Evidence suggests that performing this surgery early, within 24 hours, and ideally before signs of herniation appear, improves both survival and functional outcomes. Waiting until the patient has already deteriorated clinically may be too late to provide meaningful benefit.17PubMed Central. Timing of Decompressive Craniectomy for Ischemic Stroke and Traumatic Brain Injury: A Review
Preventing a Second Stroke
Surviving a stroke is only half the battle. The risk of having another one is highest in the first weeks and months, and the medications started in the hospital play a major role in reducing that risk. Two pillars of secondary prevention stand out: antiplatelet therapy and statin therapy.
For minor strokes, starting two antiplatelet drugs together (dual antiplatelet therapy) early on reduces the chance of recurrence. A large trial found that adding clopidogrel to aspirin within 72 hours of a stroke cut the rate of new strokes from about 9 percent to about 7 percent over the follow-up period, though the combination also roughly doubled the risk of moderate-to-severe bleeding, from about 0.4 to 0.9 percent.18PubMed. Dual Antiplatelet Treatment up to 72 Hours after Ischemic Stroke A network meta-analysis comparing different dual antiplatelet combinations found that both ticagrelor-plus-aspirin and clopidogrel-plus-aspirin were superior to aspirin alone for preventing recurrent stroke.19PubMed. Ticagrelor versus clopidogrel in dual antiplatelet therapy after minor stroke or transient ischemic attack: an updated network meta-analysis Dual antiplatelet therapy is typically given for a limited period (often 21 to 90 days) and then stepped down to a single agent, because the bleeding risk increases over time.
High-intensity statin therapy is the other cornerstone. The landmark SPARCL trial showed that high-dose atorvastatin started after a stroke or TIA reduced the rate of future strokes by about 16 percent and major cardiovascular events by 20 percent over roughly five years.20PubMed. High-Dose Atorvastatin after Stroke or Transient Ischemic Attack And the benefit appears to depend heavily on both the dose and how consistently the patient takes it: among patients with good adherence, those on high-intensity statins had roughly half the risk of adverse events compared with those on low-intensity statins.21PubMed. Effects of Statin Intensity and Adherence on the Long-Term Prognosis After Acute Ischemic Stroke The message is clear: not just any statin at any dose, but high-dose and taken consistently.
Rehabilitation and the Recovery Window
Recovery after stroke is not a passive process. Both animal research and clinical studies consistently show that active rehabilitation drives real structural changes in the brain, increasing the cortical areas devoted to functions that were impaired. Delays in starting rehabilitation reduce those gains, and higher-intensity therapy produces better outcomes.22PubMed. The role of timing and intensity of rehabilitation therapies The traditional view was that most recovery happens in the first three to six months and then plateaus. That view is being revised. A study using detailed measurements found that meaningful improvement in body function was still achievable even in late chronic stages, well beyond the first year, with an enhanced sensitivity to treatment that extended past 12 months after the stroke.23PubMed Central. A critical time window for recovery extends beyond one-year post-stroke
This does not mean the timing does not matter. The first months remain the period of greatest neuroplasticity, and early, intensive rehabilitation during that window produces the strongest gains. But the finding that improvement remains possible later challenges the common practice of reducing or discontinuing therapy after the first year, and it gives patients reason for optimism even if their initial recovery is slow.
Depression and Cognitive Problems After Stroke
The consequences of stroke extend well beyond the physical deficits most people associate with it. Depression is strikingly common: one study found that more than half of stroke patients met criteria for depression at three months, and about 42 percent still did at one year.24PubMed. Poststroke depression correlates with cognitive impairment and neurological deficits Post-stroke depression is not simply a reaction to disability. It is linked to the brain injury itself and is associated with worsened cognitive function, particularly in memory, attention, and problem-solving.
Cognitive impairment after stroke is common in the first year and, while it improves for some people, up to a third of stroke survivors develop dementia within five years. The underlying mechanism likely involves the acute stroke triggering a chain of pathological changes, often on top of pre-existing age-related brain changes that the person may not have been aware of.25PubMed Central. Cognitive Impairment After Ischemic and Hemorrhagic Stroke: A Scientific Statement From the American Heart Association/American Stroke Association The domains most often affected include executive function, memory, language, and processing speed.26PubMed Central. Association among depression, cognitive impairment and executive dysfunction after stroke Screening for both depression and cognitive decline should be a routine part of post-stroke follow-up, yet it is often underemphasized in clinical practice.
Mobile Stroke Units and Getting Treatment Earlier
One of the most promising developments in stroke care is the mobile stroke unit, an ambulance equipped with a CT scanner, lab equipment, and a direct telemedicine link to a stroke neurologist. The concept is simple: if you cannot get the patient to the hospital fast enough, bring the hospital to the patient. A scoping review of 13 studies found that mobile stroke units consistently cut the time from symptom onset to thrombolysis by 20 to 41 minutes compared with standard ambulance transport.27PubMed Central. Effectiveness of mobile stroke units in reducing time to thrombolysis in acute ischemic stroke: a scoping review In the BEST-MSU trial, the median time from symptoms to treatment was 86 minutes with the mobile unit versus 122 minutes with conventional care.
These time savings translate to real clinical differences. Patients treated by mobile stroke units were more than twice as likely to receive thrombolysis within the first 60 minutes of symptom onset, the so-called “golden hour” when treatment is most effective.28PubMed. Outcomes of Patients Receiving Thrombolysis in a Mobile Stroke Unit: A 4-Year Retrospective, Observational, Single-Center Study The challenge is cost and scalability: mobile stroke units require expensive equipment and specialized staff, and they are currently available in only a handful of cities worldwide.
Who Gets Treated and Who Does Not
Access to stroke treatment is not equal. A systematic review of U.S. stroke care found persistent racial and ethnic disparities at every step of the care chain. White patients were estimated to use emergency medical services at higher rates than Black, Asian, and Hispanic patients. A larger proportion of White patients arrived at the hospital within three hours of symptom onset (about 37 percent, compared with roughly 26 percent for Black patients and 29 percent for Hispanic patients). And White patients received clot-busting drugs at higher rates than all other groups.29PubMed. Evidence-Based Disparities in Stroke Care Metrics and Outcomes in the United States: A Systematic Review
A comprehensive meta-analysis quantified these disparities further: Black patients had significantly lower odds of receiving either intravenous thrombolysis or mechanical thrombectomy compared with White patients. Patients from lower socioeconomic backgrounds and rural areas faced similarly reduced odds. Rural patients had particularly low rates of thrombectomy, and were significantly less likely to arrive at the hospital in time to qualify for treatment.30PubMed. Disparities in Access to Reperfusion Therapy for Acute Ischemic Stroke (DARTS): A Comprehensive Meta-Analysis of Ethnicity, Socioeconomic Status, and Geographical Factors The consequences are not abstract: longer times to treatment directly translate to worse long-term disability and reduced independence.31PubMed Central. Addressing Disparities in Acute Stroke Management and Prognosis
The Gut-Brain Connection After Stroke
One of the more surprising areas of stroke research in recent years involves the gut. Acute ischemic stroke rapidly disrupts the balance of bacteria in the intestines, and those changes in gut bacteria appear to feed back into the brain’s inflammatory response. The gut microbiota is now considered a central regulator of immune function after stroke, with a potential role in determining how much damage ultimately occurs.32PubMed Central. Gut Microbiota in Acute Ischemic Stroke: From Pathophysiology to Therapeutic Implications Animal studies have demonstrated that the communication is genuinely two-way: brain injury alters the gut microbiome, and in turn, changes in the gut microbiome affect neuroinflammation and functional recovery.33Journal of Neuroscience. Microbiota Dysbiosis Controls the Neuroinflammatory Response after Stroke
The gut microbiota modulates post-stroke inflammation through immune, neural, and hormonal pathways.34PubMed Central. Gut microbiota-mediated neuroinflammation following stroke: mechanisms and intervention strategies This research is still largely in the experimental phase, and no microbiome-based therapy has been proven effective in stroke patients yet. But it opens an intriguing question: could interventions targeting the gut, whether through probiotics, dietary changes, or other means, one day serve as an adjunct to conventional stroke treatment?
Why Neuroprotective Drugs Keep Failing
For decades, researchers have searched for drugs that could shield brain cells from damage during a stroke, buying time before blood flow is restored. The concept is compelling: a neuroprotective agent given early could extend the survival time of the penumbra and minimize the final size of the infarct. In animal models, dozens of compounds have shown promise. In humans, not a single neuroprotective drug has gained approval for ischemic stroke.35Exploration of Neuroprotective Therapy. Neuroprotective agents in acute ischemic stroke
The reasons for this disconnect are instructive. One major problem is timing: many clinical trials have administered these drugs six or more hours after symptom onset, likely past the point where protecting the penumbra is still possible. The ischemic cascade moves fast, and an agent that works at 30 minutes in a mouse may be useless at six hours in a human. Other challenges include the difficulty of translating animal models to human brain injuries (which are far more variable in size, location, and underlying health) and the inherent complexity of targeting a cascade that involves dozens of interconnected pathological processes simultaneously. The search continues, but the field has learned to be cautious about promising laboratory results that have not yet survived contact with human clinical reality.